Optimization of sulphuric acid pre-treatment of Acacia saw dust through box-bhenken design for cellulase production by B. Subtilis

Background: Cellulases are enzymes which are capable of degrading lignocellulosic biomass. The current study is centred on optimization of dilute sulphuric acid pre-treatment of Acacia saw dust for maximizing cellulase production (CMCase and FPase). Hydrolysis or saccharification of lignocellulosic biomass is brought about by cellulases and the sugar thus released can be used for further bioethanol production.Methods: Box- Bhenken design (BBD) was employed for optimization of pre-treatment conditions for Acacia saw dust. Three variables i.e. sulphuric acid concentration (0.6%, 0.8% and 1.0% v/v), substrate concentration (5%,10% and15%)  and reaction time (4h,6h and 8h) was optimized. The pre-treated saw dust was used in the study as a substrate for producing cellulase enzyme through submerged fermentation by Bacillus subtilis (K-18).Results: An optimum conditions i.e. (0.8% H2SO4 conc., 15% substrate conc. and 4h of reaction time) yielded highest filter paper activity (1.3617 IU/ml/min) and CMCase activity (0.7783 IU/ml/min). The suggested model was significant as revealed by F-value, coefficient of determination (R2) andP-value.Conclusion: Results concluded that pre-treated substrate (Acacia sawdust) significantly increased cellulase production as compared to untreated substrate that could be utilized for further biofuel production

A Short History of Evolution of Indigenous Plants and Medicine System

The importance of plants is well known to us. Life and its growth cannot be imagined without plants. Food for our survival is produced by plants and they also create a healthy and eco-friendly environment to live (Sazada et al., 2009).The use of various parts of different medicinal plants to cure specific ailments has been common from ancient times in India. The indigenous system of medicine namely Ayurvedic, Siddha and Unani have been in existence for many centuries. Apart from India, these systems are also prominent in Korea, China, Singapore, West Asia and many other countries. The knowledge of medicinal plants has been inherited traditionally therefore; the utilization of this knowledge has become important for human existence. In the old times, plants were used as remedies for the diseases. The oldest religious book of the World “Rigveda” provides information about the medicinal use of plant “Soma” as a medicinal agent by the Indo-Aryans, which was written between 4000 and 1600 B.C. (Bhattacharjee, 2004).The plant “Soma” is considered to have intoxicating characteristics. This plant is used for sacrificial objectives by Aryans and they also identified its juice as a stimulating beverage (Steiner, 1986). The Aryans also played a vital role in the presentation of therapeutical properties of other medicinal herbs and plants. The knowledge of Aryans about a large number of medicinal plants is demonstrated by the work of Charaka and Sushruta (Kirtikar, 1958).The ancient Indian literature is helpful in driving the current knowledge of using cinchona in malaria, digitalis, strophanthus and physostigma in heart diseases and of quassia as a bitter tonic. The indigenous system of medicine in the Indian sub-continent known as Ayurveda goes back to 700 B.C. and its systematization is attributed mostly to Charaka and Sushruta who have cited about 700 medicinal plants. The book “Sushruta Samhita” compiled in 1000 B.C. includes a comprehensive chapter on herbal therapeutics and contains remarkable information about the use of medicinal plants (Singh and Abrar, 1990)

Geospatial Dynamics of SARS-CoV-2 Variants during the Fifth Wave of COVID-19 in Punjab, Pakistan

Background: The study was conducted in the various districts of Punjab, Pakistan, to ascertain the incidence and epidemiology of SARS-CoV-2 variants circulating in the population during the fifth wave of COVID-19.Method: A total of 9603 nasopharyngeal swab samples of suspected patients were collected from the different districts of Punjab from December 2021 to April 2022. In the BSL-3 facility, an auto-extractor (Uni-medica) was used to extract the RNA genome. Viral detection and quantification were performed using real-time reverse transcriptase PCR. Multiplex PCR was used to target different mutations of the spike protein in order to identify SARS-CoV-2 variants.Results: 711 samples were found to be positive from a total of 9603. The Omicron variant of concern (VOC) was the predominant lineage of SARS-CoV-2 circulating at the time of sampling. Ninety-one percent proportion of COVID-19 was caused by the Omicron, followed by the wild variant (3.80%) and Delta (68.11%). Men were found to have a greater Omicron prevalence (47.96%) than women (42.05%). Furthermore, compared to older individuals (32.07%) and younger kids (10.55%), adults had the higher percentage of Omicron (47.39%).Conclusion: This study brought attention to the Omicron variant's circulation in Punjab Province, Pakistan, during the COVID-19 fifth wave.Keywords: Coronavirus; Omicron; Delta; Variant of Concern; Multiplex PCR; Punjab; Pandemic 

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention